Partial
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely omit approved indications and many safety/usage details for atorvastatin, while correctly reflecting some pharmacology and administration nuances. Several B12-related assertions are not supported by the provided labeling. Overall, the response shows partial alignment with the label, with notable omissions and unsupported statements.
Category Scores
Accurate Statements
Atorvastatin inhibits HMG-CoA reductase.
12.1
Atorvastatin metabolism involves cytochrome P450 3A4.
12.3
Atorvastatin can be taken with or without food.
12.3, 2 DOSAGE AND ADMINISTRATION
Unsupported Statements
No clinically significant interaction is known between vitamin B12 and atorvastatin.
Label 7 lists drug interactions but does not mention vitamin B12.
You can safely take them together; there’s no need to adjust doses or timing.
No label guidance specifically stating B12-atorvastatin coadministration is without dose/timing adjustments.
Vitamin B12 is absorbed in the ileum with intrinsic factor.
No information about vitamin B12 absorption is provided in shown label sections.
Vitamin B12 is stored mainly in the liver.
No information about vitamin B12 storage is provided in shown label sections.
Interaction potential: No shared metabolic pathway.
Label does not discuss vitamin B12 metabolism or shared pathways with atorvastatin.
Atorvastatin can rarely cause myopathy or mild anemia.
Label notes myopathy risk with statins and certain drug interactions; does not state anemia as a statin-related effect.
B12 is not metabolized by CYP enzymes.
Label does not address B12 metabolism.
No competition for the same enzymes.
No label statement about B12 competing for the same enzymes as atorvastatin.
B12 is water-soluble, not affected by lipid-soluble drug metabolism.
Label does not discuss B12 solubility or lipid-soluble drug metabolism.
No effect on B12 levels.
No information about B12 level changes with atorvastatin is provided.
No direct effect, but correcting a B12 deficiency might help if neuropathic symptoms are present.
No label discussion about correcting B12 deficiency affecting neuropathic symptoms with atorvastatin.
No dose adjustment is needed when starting B12 with atorvastatin.
No dosing guidance about B12 coadministration with atorvastatin.
Water-soluble vitamins are excreted unchanged; excess is usually harmless.
No label statement regarding water-soluble vitamins' excretion or excess safety.
B12 does not interfere with the cholesterol-lowering effect of atorvastatin.
No statement about B12 interference with atorvastatin’s lipid-lowering effect is present.
You can confidently take vitamin B12 and atorvastatin together without any special precautions.
No labeling guidance about coadministration or precautions specific to their together use.
If you have symptoms (muscle pain, weakness, fatigue), tell your provider; sometimes a simple B12 check can explain and improve those symptoms.
No label guidance linking symptom evaluation to B12 checks is shown.
Keep on track with both your statin therapy and B12 supplementation as directed.
No label instruction linking B12 supplementation to statin therapy management.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Pregnancy safety information not shown (8.1 Pregnancy).
Importance:
High
Pediatric safety information not shown (8.4 Pediatric Use).
Importance:
Moderate
Contraindications not shown (4 CONTRAINDICATIONS).
Importance:
High
Explicit safety cautions or guidance about B12 coadministration with statins (timing, dose adjustments) not shown.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The label acknowledges limited drug interaction risk profiles for atorvastatin (with specific drugs) and confirms standard administration flexibility; no B12-specific safety signals are described in the shown sections.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
Explicitly state that there is no approved interaction data between vitamin B12 and atorvastatin in the label, and consider adding clarifying statements about absorption/timing for atorvastatin and any B12-related safety considerations if clinically warranted. Include pregnancy and pediatric use sections in the provided label excerpts to avoid safety omissions.